mFOLFOX6
Showing 1 - 25 of 346
Colorectal Cancer, Liver Metastases Trial in Shanghai (mFOLFOX6 + Cetuximab, mFOLFOX 6)
Not yet recruiting
- Colorectal Cancer
- Liver Metastases
- mFOLFOX6 + Cetuximab
- mFOLFOX 6
-
Shanghai, ChinaZhongshan hosptial, Fudan University
Jul 14, 2023
Colorectal Cancer Trial in Shanghai (Fruquintinib+mFOLFOX6/FOLFIRI)
Recruiting
- Colorectal Cancer
-
Shanghai, Shanghai, ChinaFudan University Shanghai Cancer Center
Aug 23, 2023
Multiple Cancer, Colorectal Cancer Trial (MSI-H/MSS (dMMR/pMMR) mixed sMPCC: combination of mFOLFOX6+PD-1 mAb neoadjuvant
Not yet recruiting
- Multiple Cancer
- Colorectal Cancer
- MSI-H/MSS (dMMR/pMMR) mixed sMPCC: combination of mFOLFOX6+PD-1 monoclonal antibody neoadjuvant therapy
- All-MSI-H (dMMR) sMPCC: single-drug PD-1 monoclonal antibody neoadjuvant therapy
- (no location specified)
Aug 20, 2023
Metastatic Colorectal Cancer Trial in Wuhan (Fruquintinib Combined With mFOLFOX6/FOLFIRI)
Recruiting
- Metastatic Colorectal Cancer
- Fruquintinib Combined With mFOLFOX6/FOLFIRI
-
Wuhan, Hubei, ChinaZhongnan Hopital of Wuhan University
Oct 25, 2022
Colorectal Cancer Trial in Guangzhou (mFOLFOXIRI + Cadonilimab, mFOLFOX6)
Not yet recruiting
- Colorectal Cancer
- mFOLFOXIRI + Cadonilimab
- mFOLFOX6
-
Guangzhou, Guangdong, ChinaGastrointestinal Hospital, Sun Yat-sen University
Oct 17, 2022
Metastatic Colorectal Cancer Trial (Cetuximab + Envafolimab + mFOLFOXIRI, Cetuximab + mFOLFOX6/FOLFIRI)
Not yet recruiting
- Metastatic Colorectal Cancer
- Cetuximab + Envafolimab + mFOLFOXIRI
- Cetuximab + mFOLFOX6/FOLFIRI
- (no location specified)
Jul 24, 2023
Peritoneal Carcinomatosis Trial in Baltimore (Intraperitoneal docetaxel)
Recruiting
- Peritoneal Carcinomatosis
- Intraperitoneal docetaxel
-
Baltimore, MarylandJohns Hopkins University
Nov 7, 2022
Advanced/Metastatic Colorectal Cancer Trial in Guangzhou (Dalpiciclib, Oxaliplatin injection, Calcium folinate)
Not yet recruiting
- Advanced/Metastatic Colorectal Cancer
- Dalpiciclib
- +3 more
-
Guangzhou, Guangdong, ChinaSixth Affiliated Hospital, Sun Yat-sen University
Jul 28, 2022
Gastric Cancer, Gastroesophageal-junction Cancer, Advanced Cancer Trial (TST001, CapOx or mFOLFOX6 and NIVO or (Substudy)
Not yet recruiting
- Gastric Cancer
- +2 more
- TST001, CapOx or mFOLFOX6 and NIVO or (Substudy) TST001, Oxaliplatin and capecitabine or 5-fluorouracil (5-FU)
- Placebo CapOx or mFOLFOX6 and NIVO or (Substudy) Placebo, Oxaliplatin and capecitabine or 5-fluorouracil (5-FU)
- (no location specified)
Oct 16, 2023
Colon Cancer, Neoadjuvant Therapy Trial in Hangzhou (Camrelizumab , apatinib and chemo)
Recruiting
- Colon Cancer
- Neoadjuvant Therapy
- Camrelizumab , apatinib and chemotherapy
-
Hangzhou, Zhejiang, ChinaFirst affiliated hospital, Zhejiang University
Jan 27, 2023
Hepatocellular Carcinoma Trial in Changsha (No interventions.)
Recruiting
- Hepatocellular Carcinoma
- No interventions.
-
Changsha, Hunan, ChinaLiangrong Shi
Jun 27, 2023
Colorectal Cancer Trial in Guangzhou (mFOLFOXIRI plus Bevacizumab, mFOLFOX6 Plus Bevacizumab)
Recruiting
- Colorectal Cancer
- mFOLFOXIRI plus Bevacizumab
- mFOLFOX6 Plus Bevacizumab
-
Guangzhou, Guangdong, ChinaGastrointestinal Hospital, Sun Yat-sen University
Jun 15, 2022
Colorectal Cancer Trial in Wenzhou (mFOLFOXIRI, mFOLFOX6 OR CapeOx)
Recruiting
- Colorectal Cancer
- mFOLFOXIRI
- mFOLFOX6 OR CapeOx
-
Wenzhou, Zhejiang, ChinaThe First Affiliated Hospital of Wenzhou Medical University
Jan 18, 2022
Metastatic Colorectal Cancer Trial in France (Panitumumab, oxaliplatin, folinic acid, 5-fluoruracil, Panitumumab, oxaliplatin,
Recruiting
- Metastatic Colorectal Cancer
- Panitumumab, oxaliplatin, folinic acid, 5-fluoruracil
- Panitumumab, oxaliplatin, folinic acid, 5-fluoruracil, irinotecan
-
Avignon, France
- +5 more
Aug 2, 2022
Chemo-refractory Colorectal Carcinoma Trial in Hamburg, Ulm (Maximum tolerated dose, MTD: D,L-methadone HCl (Methasan® 10
Recruiting
- Chemo-refractory Colorectal Carcinoma
- Maximum tolerated dose, MTD: D,L-methadone hydrochloride (Methasan® 10 mg/ml)
-
Hamburg, Germany
- +1 more
Apr 21, 2022
Stage III Colon Cancer Trial in Pittsburgh (Signatera test, mFOLFOX6 3-6 month, CAPOX 3 month)
Recruiting
- Stage III Colon Cancer
- Signatera test
- +5 more
-
Pittsburgh, PennsylvaniaNRG Oncology - Pittsburgh Center
Mar 30, 2022
Biliary Tract Cancer Trial in Essen, Pamplona (mFOLFOX6, Atezolizumab and Bevacizumab)
Recruiting
- Biliary Tract Cancer
- mFOLFOX6, Atezolizumab and Bevacizumab
-
Essen, NRW, Germany
- +1 more
Nov 16, 2021
Colon Cancer Stage III Trial in Daejeon (FOLFOXIRI, mFOLFOX 6)
Recruiting
- Colon Cancer Stage III
- FOLFOXIRI
- mFOLFOX 6
-
Daejeon, Korea, Republic ofChungnam National University Hospital
Dec 17, 2021
Metastatic Colorectal Cancer Trial in Sutton (PDR001, bevacizumab, mFOLFOX6)
Terminated
- Metastatic Colorectal Cancer
- PDR001
- +2 more
-
Sutton, Surrey, United KingdomNovartis Investigative Site
Oct 7, 2021
Esophageal Carcinoma Trial in Rochester (mFOLFOX6, Chemoradiation)
Active, not recruiting
- Esophageal Carcinoma
- mFOLFOX6
- Chemoradiation
-
Rochester, New YorkUniversity of Rochester
Aug 17, 2022
Locally Advanced Rectal Carcinoma Trial (Cadonilimab Injection, Short-course radiotherapy, Consolidation chemo)
Not yet recruiting
- Locally Advanced Rectal Carcinoma
- Cadonilimab Injection
- +2 more
- (no location specified)
Mar 19, 2023